Skip Navigation

European Heart Journal 2001 22(7):554-572; doi:10.1053/euhj.2001.2610
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme

Received December 14, 2000; accepted January 16, 2001

Abstract

Aims The principal aim of the second EUROASPIRE survey was to determine in patients with established coronary heart disease whether the Joint European Societies' recommendations on coronary prevention are being followed in clinical practice.

Methods This survey was undertaken in 1999–2000 in 15 European countries: Belgium, Czech Republic, Finland, France, Germany, Greece, Hungary, Ireland, Italy, the Netherlands, Poland, Slovenia, Sweden, Spain and the U.K., in selected geographical areas and 47 centres. Consecutive patients, men and women ≤70 years were identified retrospectively with the following diagnoses: coronary artery bypass graft, percutaneous transluminal coronary angioplasty, acute myocardial infarction and myocardial ischaemia. Data collection was based on a review of medical records and interview and risk assessment at least 6 months after hospital admission.

Results 8181 medical records (25% women) were reviewed and 5556 patients (adjusted participation rate 76%) interviewed. Recording of risk factor history and risk factor measurement in hospital notes was incomplete, particularly for discharge documents. At interview (median time 1·4 years after hospital discharge), 21% of patients smoked cigarettes, 31% were obese, 50% had raised blood pressure (systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg), 58% had elevated serum total cholesterol (total cholesterol ≥5mmol.l–1) and 20% reported a medical history of diabetes. Glucose control in these diabetic patients was poor with 87% having plasma glucose >6·0mmol.l–1and 72% ≥7·0mmol.l–1. Among the patients interviewed the use of prophylactic drug therapies on admission, at discharge and at interview was as follows: aspirin or other antiplatelets drugs 47%, 90% and 86%; beta-blockers 44%, 66% and 63%; ACE inhibitors 24%, 38% and 38%; and lipid-lowering drugs 26%, 43% and 61%, respectively. With the exception of antiplatelet drugs, wide variations in the use of prophylactic drug therapies exist between countries.

Conclusions This European survey of coronary patients shows a high prevalence of unhealthy lifestyles, modifiable risk factors and inadequate use of drug therapies to achieve blood pressure and lipid goals. There is considerable potential throughout Europe to raise the standard of preventive cardiology through more effective lifestyle intervention, control of other risk factors and optimal use of prophylactic drug therapies in order to reduce coronary morbidity and mortality.

Key Words: EUROASPIRE, Euro Heart Survey, preventive cardiology, guidelines

References

  1. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J. 1997;18:1231–1248[Free Full Text]
  2. Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet. 1999;353:1547–1557[CrossRef][ISI][Medline]
  3. Pyörälä K, De Backer G, Graham I, Poole-Wilson PA, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15:1300–1331[Free Full Text]
  4. Pyörälä K. CHD prevention in clinical practice. Lancet. 1996;348:26–28
  5. Heart. 1996;75:334–342[Abstract/Free Full Text]
  6. Eur Heart J. 1997;18:1569–1582[Abstract/Free Full Text]
  7. Wood D, De Backer G, Faergeman D, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J. 1998;19:1434–1503[Free Full Text]
  8. Lancet. 2001;:
  9. Pearson TA, Peters TD. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. Am J Cardiol. 1997;80:45H–52H[CrossRef][Medline]
  10. Pearson TA, Peters TD, Feury D. Comprehensive risk reduction in coronary patients: attainment of goals of the AHA Guidelines in U.S. patients (Abstr). Circulation. 1997;96:733[Abstract/Free Full Text]
  11. Pearson TA, Peters TD, Feury D. Screening of first degree relatives after the onset of coronary disease: a missed opportunity (Abstr). Circulation. 1997;96:374
  12. Keech A, Zambahary R, Ritchie G. Hypercholesterolaemia as a risk factor for coronary heart disease in the Asia-Pacific region: The ASPAC study (Abstr). Atherosclerosis. 2000;151:83
  13. Yamamoto A, Dans A, Ritchie G, MacMahon S, Nontakanun S, Keech A. Prevalence of hypertension in CHD patients in the Asia-Pacific region: The ASPAC study (Abstr). Atherosclerosis. 2000;151:255
  14. Ritchie G, Lai M, Park Y. Prevalence of smoking among CHD patients in the Asia-Pacific: The ASPAC study (Abstr). Atherosclerosis. 2000;151:279
  15. Danchin N, Grenier O, Ferrieres J, Cambou JP. Secondary prevention of patients with acute coronary syndrome in France: results of the PREVENIR survey (Abstr). Eur Heart J. 1999;20:664
  16. Drexel H, Gaul GB, Grimm G. Secondary prevention following coronary intervention. Survey of 13 intervention centers in Austria. Wien Klin Wochenschr. 1999;111:6433–6439
  17. Attenbring MF, Hartford M, Holm G, Wiklund O, Wahrborg P, Herlitz J. Risk indicators for recurrence among patients with coronary artery disease. Problems associated with their modification. Scand Cardiovasc J. 1998;32:9–16[ISI][Medline]
  18. Sueta CA, Chowdhury M, Boccuzzi SJ. Analysis of the degree of undertreatment of hyperlipidaemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83:1303–1307[CrossRef][ISI][Medline]
  19. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med. 1998;158:1238–1244[Abstract/Free Full Text]
  20. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med. 1999;12:711–717
  21. Thiru K, Gray J, Majeed A. Management of ischaemic heart disease in primary care: towards better practice. J Public Health Med. 1999;21:179–184[Abstract/Free Full Text]
  22. Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JM. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ. 1998;316:1430–1434[Abstract/Free Full Text]
  23. Flanagan DEH, Cox R, Paine D, Davies J, Armitage M. Secondary prevention of coronary heart disease in primary care: a healthy heart initiative. QJM. 1999;92:245–250[Abstract/Free Full Text]
  24. De Velasco JA, Cosin J, Lopez-Sendon JL. La prevencion secundaria del infarto de miocardio en Espana. Estudio PREVESE. (Secondary prevention of myocardial infarction in Spain. The PREVESE study). Rev Esp Cardiol. 1997;50:406–415[ISI][Medline]
  25. Velasco JA. After 4S, CARE and LIPID—is evidence-based medicine being practised? Atherosclerosis. 1999;147:S39–S44
  26. de Oya M, Lopez-Sendon JL, de Teresa E, Velasco-Rami J, Villa E, Cosin J. The impact of landmark clinical trials on secondary prevention of acute myocardial infarction (AMI) in Spain. Prevese 98 study (Abstr). Atherosclerosis. 2000;151:107
  27. Van Berkel TFM, Boersma H, Roos-Hesselink JW, Erdman RAM, Simoons ML. Impact of smoking cessation and smoking interventions in patients with coronary heart disease. Eur Heart J. 1999;20:1773–1782[Free Full Text]
  28. JAMA. 2000;283:3244–3254[Abstract/Free Full Text]
  29. Balfour D, Benowitz N, Fagerström K, Kunze M, Keil U. Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. Eur Heart J. 2000;21:438–445[Abstract/Free Full Text]
  30. Montaye M, De Bacquer D, De Backer G, Amouyel P. Overweight and obesity: a major challenge for coronary heart disease secondary prevention in clinical practice in Europe. Eur Heart J. 2000;21:808–813[Abstract/Free Full Text]
  31. Kuulasmaa K, Tunstall-Pedoe H, Dobson A. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet. 2000;355:675–687[CrossRef][ISI][Medline]
  32. Flack J, Neaton J, Grimm R. Blood pressure and mortality among men with prior myocardial infarction. Circulation. 1995;92:2437–2445[Abstract/Free Full Text]
  33. Lancet. 1994;344:1389–1389
  34. Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009[Abstract/Free Full Text]
  35. N Engl J Med. 1998;339:1349–1357[Abstract/Free Full Text]
  36. Miettinen H, Lehto S, Salomaa V. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care. 1998;21:69–75[Abstract]
  37. Löwel H, Koenig W, Engel S, Hormann A, Keil U. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. Diabetologia. 2000;43:218–226[CrossRef][ISI][Medline]
  38. Malmberg K, Rydén L, Hamsten A, Herlitz J, Waldenström A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J. 1996;17:1337–1344[Abstract/Free Full Text]
  39. Definition, diagnosis and classification of diabetes mellitus and its complications
  40. Diabet Med. 1999;16:716–730[CrossRef][ISI][Medline]
  41. BMJ. 1994;308:81–106[Abstract/Free Full Text]
  42. Lancet. 1996;348:1329–1339[CrossRef][ISI][Medline]
  43. Gottlieb SS, McCarter RJ, Vogel RA. Effects of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Eng J Med. 1998;339:489–497[Abstract/Free Full Text]
  44. Freemantle N, Cleland J, Young P, Mason J, Harrisson J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730–1737[Abstract/Free Full Text]
  45. Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol. 1999;33:598–604[Abstract/Free Full Text]
  46. N Engl J Med. 2000;342:145–153[Abstract/Free Full Text]
  47. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA. 1999;282:2058–2067[Abstract/Free Full Text]
  48. Feely J. The therapeutic gap—compliance with medication and guidelines. Atherosclerosis. 1999;147:S31–S37
  49. Shepherd J. From best evidence to best practice—what are the obstacles? Atherosclerosis. 1999;147:S45–S51
  50. Shepherd J. International comparison of awareness and attitudes towards coronary risk factor reduction: The HELP study. Atherosclerosis. 1998;137:S117–S123

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Public HealthHome page
K. M. Nielsen, O. Faergeman, A. Foldspang, and M. L. Larsen
Cardiac rehabilitation: health characteristics and socio-economic status among those who do not attend
Eur J Public Health, July 9, 2008; (2008) ckn060v1.
[Abstract] [Full Text] [PDF]

Home page
 ICVTSHome page
A. J. Turley, A. P. Roberts, R. Morley, A. R. Thornley, W. A. Owens, and M. A. de Belder
Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up
Interactive CardioVascular and Thoracic Surgery, April 1, 2008; 7(2): 231 - 234.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
L. G. Mellbin, K. Malmberg, A. Norhammar, H. Wedel, L. Ryden, and for the DIGAMI 2 Investigators
The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial
Eur. Heart J., January 2, 2008; 29(2): 166 - 176.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S Capewell and M O'Flaherty
Maximising secondary prevention therapies in patients with coronary heart disease
Heart, January 1, 2008; 94(1): 8 - 9.
[Full Text] [PDF]

Home page
 HeartHome page
K. Khunti, M. Stone, S. Paul, J. Baines, L. Gisborne, A. Farooqi, X. Luan, and I. Squire
Disease management programme for secondary prevention of coronary heart disease and heart failure in primary care: a cluster randomised controlled trial
Heart, November 1, 2007; 93(11): 1398 - 1405.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Public HealthHome page
R. Gnavi, A. Migliardi, M. Demaria, A. Petrelli, A. Caprioglio, and G. Costa
Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities
Eur J Public Health, October 1, 2007; 17(5): 492 - 496.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74.
[Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
D. Wood
The concept of doctor targets based on quality guidelines: focus on blood pressure
Eur. Heart J. Suppl., May 1, 2007; 9(suppl_B): B29 - B36.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al.
Anticoagulants in heart disease: current status and perspectives
Eur. Heart J., April 10, 2007; (2007) ehl492v1.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J., January 1, 2007; 28(1): 88 - 136.
[Full Text] [PDF]

Home page
 HypertensionHome page
G. Mancia
Effective Ambulatory Blood Pressure Control in Medical Practice: Good News To Be Taken With Caution
Hypertension, January 1, 2007; 49(1): 17 - 18.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
C. J. Boos, G. Y.H. Lip, and A. D. Blann
Circulating Endothelial Cells in Cardiovascular Disease
J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1538 - 1547.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
T. R. Pedersen
The gap between theory and practice: what do the trials tell us?
Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F10 - F16.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
Z. Kabir, K. Bennett, E. Shelley, B. Unal, J. Critchley, J. Feely, and S. Capewell
The population mortality benefits of maximizing the number of eligible patients receiving appropriate cardiology treatments in Ireland
QJM, August 1, 2006; 99(8): 523 - 530.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
G. H. Gislason, S. Jacobsen, J. N. Rasmussen, S. Rasmussen, P. Buch, J. Friberg, T. K. Schramm, S. Z. Abildstrom, L. Kober, M. Madsen, et al.
Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction
Circulation, June 27, 2006; 113(25): 2906 - 2913.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
G. H. Gislason, J. N. Rasmussen, S. Z. Abildstrom, N. Gadsboll, P. Buch, J. Friberg, S. Rasmussen, L. Kober, S. Stender, M. Madsen, et al.
Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction
Eur. Heart J., May 2, 2006; 27(10): 1153 - 1158.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
N Sambu, D S Wald, M Seddon, and I A Simpson
Undertreatment of coronary heart disease in patients undergoing coronary artery bypass surgery.
Heart, May 1, 2006; 92(5): 697 - 698.
[Full Text] [PDF]

Home page
 HeartHome page
S Capewell, B Unal, J A Critchley, and J J V McMurray
Over 20,000 avoidable coronary deaths in England and Wales in 2000: the failure to give effective treatments to many eligible patients.
Heart, April 1, 2006; 92(4): 521 - 523.
[Full Text] [PDF]

Home page
 West J Nurs ResHome page
A. M. Clark
Commentary by Clark
West J Nurs Res, March 1, 2006; 28(2): 210 - 213.
[PDF]

Home page
 Eur Heart JHome page
W. Scholte op Reimer, E. de Swart, D. De Bacquer, K. Pyorala, U. Keil, J. Heidrich, J. W. Deckers, K. Kotseva, D. Wood, E. Boersma, et al.
Smoking behaviour in European patients with established coronary heart disease
Eur. Heart J., January 1, 2006; 27(1): 35 - 41.
[Abstract] [Full Text] [PDF]

Home page
 J. Epidemiol. Community HealthHome page
I Gemmell, R F Heller, P McElduff, K Payne, G Butler, R Edwards, M Roland, and P Durrington
Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease
J. Epidemiol. Community Health, December 1, 2005; 59(12): 1041 - 1046.
[Abstract] [Full Text] [PDF]

Home page
 J Public Health (Oxf)Home page
S. E. Ramsay, R. W. Morris, O. Papacosta, L. T. Lennon, M. C. Thomas, and P. H. Whincup
Secondary prevention of coronary heart disease in older British men: extent of inequalities before and after implementation of the National Service Framework
J. Public Health Med., December 1, 2005; 27(4): 338 - 343.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
Prepared by: British Cardiac Society, British Hype
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Heart, December 1, 2005; 91(suppl_5): v1 - v52.
[Full Text] [PDF]

Home page
 ANGIOLOGYHome page
E. J. Diamantopoulos, V. G. Athyros, G. K. Yfanti, E. N. Migdalis, M. Elisaf, P. E. Vardas, A. S. Manolis, D. T. Karamitsos, E. S. Ganotakis, D. Hatseras, et al.
The contrOL of dYslipideMia in outPatIent clinics in GreeCe (Olympic) Study
Angiology, November 1, 2005; 56(6): 731 - 741.
[Abstract] [PDF]

Home page
 Eur Heart J SupplHome page
D. A. Wood
Guidelines on cardiovascular risk assessment and management
Eur. Heart J. Suppl., November 1, 2005; 7(suppl_L): L5 - L10.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
L. R. Erhardt
Managing cardiovascular risk: reality vs. perception
Eur. Heart J. Suppl., November 1, 2005; 7(suppl_L): L11 - L15.
[Abstract] [Full Text] [PDF]

Home page
 Scand J Public HealthHome page
A.-D. O. Zwisler, U. I. Traeden, J. Videbaek, and M. Madsen
Cardiac rehabilitation services in Denmark: Still room for expansion
Scand J Public Health, October 1, 2005; 33(5): 376 - 383.
[Abstract] [PDF]

Home page
 HeartHome page
A M Clark, I N Findlay, and for the Have a Heart Paisley IT Group
Improving evidence based cardiac care and policy implementation over the patient journey: the potential of coronary heart disease registers
Heart, September 1, 2005; 91(9): 1127 - 1130.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
H Narchi
Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review
Arch. Dis. Child., September 1, 2005; 90(9): 916 - 920.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J.A. Iestra, D. Kromhout, Y.T. van der Schouw, D.E. Grobbee, H.C. Boshuizen, and W.A. van Staveren
Effect Size Estimates of Lifestyle and Dietary Changes on All-Cause Mortality in Coronary Artery Disease Patients: A Systematic Review
Circulation, August 9, 2005; 112(6): 924 - 934.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
B. Roca, C. Suarez, A. Ceballos, J.M. Varela, F. Nonell, J. Montes, J. Sobrino, A. de la Pena, and for the CIFARC Group
Control of hypertension in patients at high risk of cardiovascular disease
QJM, August 1, 2005; 98(8): 581 - 588.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
F. Fernandez-Aviles
Introduction: Diagnostic and interventional procedures for coronary artery disease: implications for selection of contrast media
Eur. Heart J. Suppl., August 1, 2005; 7(suppl_G): G1 - G3.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
C. A. Daly, K. M. Fox, W. J. Remme, M. E. Bertrand, R. Ferrari, M. L. Simoons, and on behalf of the EUROPA investigators
The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy
Eur. Heart J., July 2, 2005; 26(14): 1369 - 1378.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
J.-P. Bassand, S. Priori, and M. Tendera
Evidence-based vs. 'impressionist' medicine: how best to implement guidelines
Eur. Heart J., June 2, 2005; 26(12): 1155 - 1158.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
C. A. Daly, F. Clemens, J. L. L. Sendon, L. Tavazzi, E. Boersma, N. Danchin, F. Delahaye, A. Gitt, D. Julian, D. Mulcahy, et al.
The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina
Eur. Heart J., May 2, 2005; 26(10): 996 - 1010.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
C. A. Daly, F. Clemens, J. L. L. Sendon, L. Tavazzi, E. Boersma, N. Danchin, F. Delahaye, A. Gitt, D. Julian, D. Mulcahy, et al.
The initial management of stable angina in Europe, from the Euro Heart Survey: A description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina
Eur. Heart J., May 2, 2005; 26(10): 1011 - 1022.
[Abstract] [Full Text] [PDF]

Home page
 Med Decis MakingHome page
A. Gandjour and K. W. Lauterbach
How Much Does It Cost to Change the Behavior of Health Professionals? A Mathematical Model and an Application to Academic Detailing
Med Decis Making, May 1, 2005; 25(3): 341 - 347.
[Abstract] [PDF]

Home page
 HeartHome page
T N Martin, R J Irving, M Sutherland, K Sutherland, and P Bloomfield
Improving secondary prevention in coronary bypass patients: closing the audit loop
Heart, April 1, 2005; 91(4): 456 - 459.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
P M Underwood, L S Cozma, K Laji, H Cohen, K Oboubie, and P Beck
Secondary prevention of coronary heart disease in South Wales: a survey following myocardial infarction
Heart, November 1, 2004; 90(11): 1332 - 1333.
[Full Text] [PDF]

Home page
 Cardiovasc ResHome page
G. Kojda
Direct vasoprotection by aspirin: a significant bonus to antiplatelet activity?
Cardiovasc Res, November 1, 2004; 64(2): 192 - 194.
[Full Text] [PDF]

Home page
 HeartHome page
J S Birkhead, L Walker, M Pearson, C Weston, A D Cunningham, and A F Rickards
Improving care for patients with acute coronary syndromes: initial results from the National Audit of Myocardial Infarction Project (MINAP)
Heart, September 1, 2004; 90(9): 1004 - 1009.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
F.D.R. Hobbs
Guidelines and management of global risk: the European perspective
Eur. Heart J. Suppl., July 1, 2004; 6(suppl_C): C5 - C14.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
A.L. McLeod, L. Brooks, V. Taylor, P.F. Currie, and N.G. Dewhurst
Secondary prevention for coronary artery disease
QJM, March 1, 2004; 97(3): 127 - 131.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
H. D. White and J. T. Willerson
We Must Use the Knowledge That We Have to Treat Patients With Acute Coronary Syndromes
Circulation, February 17, 2004; 109(6): 698 - 700.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
D. De Bacquer, G. De Backer, D. Cokkinos, U. Keil, M. Montaye, E. Ostor, K. Pyorala, S. Sans, and for the EUROASPIRE II Study Group
Overweight and obesity in patients with established coronary heart disease: Are we meeting the challenge?
Eur. Heart J., January 2, 2004; 25(2): 121 - 128.
[Abstract] [Full Text] [PDF]

Home page
 J. Epidemiol. Community HealthHome page
O Mayer Jr, J Simon, J Heidrich, D V Cokkinos, and D De Bacquer
Educational level and risk profile of cardiac patients in the EUROASPIRE II substudy
J. Epidemiol. Community Health, January 1, 2004; 58(1): 47 - 52.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
A. R.J. Mitchell and N. Sulke
How do atrial pacing algorithms prevent atrial arrhythmias?
Europace, January 1, 2004; 6(4): 351 - 362.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J